437 related articles for article (PubMed ID: 10515681)
1. Interleukin-3 in hematology and oncology: current state of knowledge and future directions.
Mangi MH; Newland AC
Cytokines Cell Mol Ther; 1999 Jun; 5(2):87-95. PubMed ID: 10515681
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-3: Promises and Perspectives.
Mangi MH; Newland AC
Hematology; 1998; 3(1):55-66. PubMed ID: 27416283
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
[TBL] [Abstract][Full Text] [Related]
4. Special Education: Aplastic Anemia.
Teramura M; Mizoguchi H
Oncologist; 1996; 1(3):187-189. PubMed ID: 10387986
[TBL] [Abstract][Full Text] [Related]
5. Present and future clinical relevance of interleukin 3.
Gianella-Borradori A
Stem Cells; 1994; 12 Suppl 1():241-8. PubMed ID: 7696963
[TBL] [Abstract][Full Text] [Related]
6. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development.
Vadhan-Raj S
Stem Cells; 1994 May; 12(3):253-61. PubMed ID: 8075592
[TBL] [Abstract][Full Text] [Related]
7. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
8. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
9. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte-macrophage colony stimulating factor and interleukin 3: target cells and kinetics of response in vivo.
Aglietta M; Pasquino P; Sanavio F; Stacchini A; Severino A; Fubini L; Morelli S; Volta C; Monteverde A; Piacibello W
Stem Cells; 1993 Jul; 11 Suppl 2():83-7. PubMed ID: 8401260
[TBL] [Abstract][Full Text] [Related]
11. 5-fluorouracil permits access to a primitive subpopulation of peripheral blood stem cells.
Rice A; Barbot C; Lacombe F; Dubosc-Marchenay N; Marit G; Hau F; Boiron JM; Reiffers J
Stem Cells; 1993 Jul; 11(4):326-35. PubMed ID: 8401256
[TBL] [Abstract][Full Text] [Related]
12. Cytokine enhancement of peripheral blood stem cells.
Hénon PR; Becker M
Stem Cells; 1993 Jul; 11 Suppl 2():65-71. PubMed ID: 7691330
[TBL] [Abstract][Full Text] [Related]
13. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.
Peters BG; Adkins DR; Harrison BR; Velasquez WS; Dunphy FR; Petruska PJ; Bowers CE; Niemeyer R; McIntyre W; Vrahnos D; Auberry SE; Spitzer G
Bone Marrow Transplant; 1996 Jul; 18(1):93-102. PubMed ID: 8832001
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human interleukin 3 in clinical oncology.
de Vries EG; van Gameren MM; Willemse PH
Stem Cells; 1993 Mar; 11(2):72-80. PubMed ID: 8457787
[TBL] [Abstract][Full Text] [Related]
15. IL-3 and peripheral blood stem cell harvesting.
Guillaume T; D'Hondt V; Symann M
Stem Cells; 1993 May; 11(3):173-81. PubMed ID: 8100463
[TBL] [Abstract][Full Text] [Related]
16. Short-term in vivo priming of bone marrow haematopoiesis with rhG-CSF, rhGM-CSF or rhIL-3 before marrow harvest expands myelopoiesis but does not improve engraftment capability.
Hansen PB; Knudsen H; Gaarsdal E; Jensen L; Ralfkiaer E; Johnsen HE
Bone Marrow Transplant; 1995 Sep; 16(3):373-9. PubMed ID: 8535309
[TBL] [Abstract][Full Text] [Related]
17. Circular permutation of the granulocyte colony-stimulating factor receptor agonist domain of myelopoietin.
McWherter CA; Feng Y; Zurfluh LL; Klein BK; Baganoff MP; Polazzi JO; Hood WF; Paik K; Abegg AL; Grabbe ES; Shieh JJ; Donnelly AM; McKearn JP
Biochemistry; 1999 Apr; 38(14):4564-71. PubMed ID: 10194378
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects.
Veltri S; Smith JW
Stem Cells; 1996 Mar; 14(2):164-76. PubMed ID: 8991536
[TBL] [Abstract][Full Text] [Related]
19. Preclinical ex vivo expansion of G-CSF-mobilized peripheral blood stem cells: effects of serum-free media, cytokine combinations and chemotherapy.
Li K; Li CK; Chuen CK; Tsang KS; Fok TF; James AE; Lee SM; Shing MM; Chik KW; Yuen PM
Eur J Haematol; 2005 Feb; 74(2):128-35. PubMed ID: 15654904
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321.
Anderson JE; Appelbaum FR
Curr Opin Hematol; 1994 May; 1(3):203-9. PubMed ID: 9371283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
